Systemic treatments for mesothelioma: standard and novel.
about
MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapySecond generation sequencing of the mesothelioma tumor genome.Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implicationsApoptosis by [Pt(O,O'-acac)(γ-acac)(DMS)] requires PKC-δ mediated p53 activation in malignant pleural mesothelioma.Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity.Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions.First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial.Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.In Vitro and In Vivo Antitumor Activity of [Pt(O,O'-acac)(γ-acac)(DMS)] in Malignant Pleural MesotheliomaAdaptation of a chemosensitivity assay to accurately assess pemetrexed in ex vivo cultures of lung cancerMalignant pleural mesothelioma: current and future perspectivesLate cutaneous metastases to the face from malignant pleural mesothelioma: a case report and review of the literature.Asbestos-related pleuropulmonary diseases: benign and malignant.Immune therapies for malignant mesothelioma.Parakeratotic-like cells in effusions - A clue to diagnosis of malignant mesothelioma.Medical and oncological management of malignant mesothelioma.Advances in treatment of mesothelioma.Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.In vitro anti-mesothelioma activity of cisplatin-gemcitabine combinations: evidence for sequence-dependent effects.microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma.The clinicopathological characteristics with long-term outcomes in malignant mesothelioma.Glutathione S-transferase P1-1 as a target for mesothelioma treatment.New concepts in the treatment of malignant pleural mesothelioma.Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy.Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands
P2860
Q27853125-C229A265-5D99-4B03-BDE4-1D782312CBCFQ28534042-F37249F8-8B50-4EA2-BA87-BC389EBC1B10Q33582141-D981629C-72C0-4962-9FCE-FC3E93D7F1D7Q33683134-C0D34C46-A41D-41C2-8A59-1222FAEFB7D2Q33898584-154BB664-12CD-4B55-993E-3D885F25887BQ34642678-890D1FF0-B759-42D5-8467-2529B5CE0422Q35177969-639810A4-64EB-4AF0-BD44-0F68609CCC34Q35275675-35D010B6-3FA5-46D3-8BE4-A796AE8F6265Q35832320-ADF79839-6F45-4652-9BAD-F5AAA4EFF442Q36159154-E320535E-9031-4C60-8400-96A6C17500AAQ36180331-F69B2297-F2BF-40DB-85D9-D16EE15B83E4Q36591925-C5011EBA-76E4-49AC-A482-E221DCC530BBQ37217764-DA034F89-312B-4683-A0C2-26162B7308CDQ37629910-AA1D0016-0B11-4342-8924-C08228790D36Q38018217-6A6354E8-42C8-40AB-B3FE-920D2A238990Q38212149-2913C2CC-D4C7-4BCC-B7D0-E3B1DB5986DAQ38401479-5837A650-B4AC-4396-876D-EA467030C80FQ38542421-82CDAD32-A9A9-4B10-8CE7-E3A889A8031CQ38800916-083197A0-0BBE-4C37-84AA-673979718F03Q39463417-F27E4A17-099C-4479-979D-2F650A691308Q39718655-6AC04224-B5AD-475E-B984-6776F997E197Q42412951-AA923C18-B42E-4757-956F-17718EE6963CQ51114246-FBD0F4EF-62E1-4AFC-AB14-E89A12D2D0B7Q54473737-7F9C235E-2DBB-4FDF-82C0-72CD8BD58CAEQ55235952-C739BEFE-331B-4BD1-9481-FD91FDC26B89Q55346721-D5FC45FA-F8D8-4151-90AF-ED5DF86115A4Q58588998-D652AFCF-4B5A-4D58-8147-C118DDD1FD1C
P2860
Systemic treatments for mesothelioma: standard and novel.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Systemic treatments for mesothelioma: standard and novel.
@en
Systemic treatments for mesothelioma: standard and novel.
@nl
type
label
Systemic treatments for mesothelioma: standard and novel.
@en
Systemic treatments for mesothelioma: standard and novel.
@nl
prefLabel
Systemic treatments for mesothelioma: standard and novel.
@en
Systemic treatments for mesothelioma: standard and novel.
@nl
P2860
P1476
Systemic treatments for mesothelioma: standard and novel.
@en
P2093
Hedy Lee Kindler
P2860
P2888
P304
P356
10.1007/S11864-008-0071-3
P577
2008-06-01T00:00:00Z